Resminostat: 4SC Filed Letter of Intent to the European Medicines Agency (EMA)
4SC AG (4SC, FSE Prime Standard: VSC) has now filed with EMA its letter of intent to file for Marketing Authorization for resminostat in cutaneous T cell lymphoma (CTCL) and request the appointment of rapporteurs. Given the clear benefit provided Mehr




